Adjuvant chemo-radiation for gastric adenocarcinoma: an institutional experience

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Aftimos, Philippe G ^a   Nasr, Elie A ^a   Nasr, Dolly I ^a   Noun, Roger J ^a   Nasr, Fady L ^a   Ghosn, Marwan G ^a   El Helou, Joelle A ^a   Chahine, Georges Y ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DERMATITIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LUNG EMBOLISM; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SEPTIC SHOCK; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; TOTAL PARENTERAL NUTRITION; TOTAL STOMACH RESECTION; TREATMENT PLANNING; WEIGHT REDUCTION; ADENOCARCINOMA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIATION DOSE; STOMACH TUMOR; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77953006091     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-50     Document Type: Article

References (16)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999, 80:827-41. 10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P, 10074914.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence. Mortality and prevalence worldwide. IARC cancer base no. 5, version 2.0 2004, Lyon (France): IARC Press.
3. Shamseddine A, Sibai AM, Gehchan N, Rahal B, El-Saghir N, Ghosn M, Aftimos G, Chamsuddine M, Seoud M. For The Lebanese Cancer Epidemiology Group: Cancer incidence in postwar Lebanon: findings from the first national population-based registry, 1998. Ann Epidemiol 2004, 14:663-668. 10.1016/j.annepidem.2003.12.002, 15380797.
4. Dupont JB, Lee JR, Burton GR, Cohn I. Adenocarcinoma of the stomach: review of 1,497 cases. Cancer 1978, 41:941-947. 10.1002/1097-0142(197803)41:3<941::AID-CNCR2820410323>3.0.CO;2-M, 638980.
5. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base fifth edition American Joint Committee on Cancer staging proximal disease, and the "different disease" hypothesis. Cancer 2000, 88:921-932. 10.1002/(SICI)1097-0142(20000215)88:4<921::AID-CNCR24>3.0.CO;2-S, 10679663.
6. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730. 10.1056/NEJMoa010187, 11547741.
7. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20. 10.1056/NEJMoa055531, 16822992.
8. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K. ACTS-GC Group: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357:1810-1820. 10.1056/NEJMoa072252, 17978289.
9. Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria. , http://www.rtog.org/members/toxicity/acute.html
10. Middleton G, Cunningham D. Current options in the management of gastrointestinal cancer. Ann Oncol 1995, 6(Suppl 1):17-25. discussion 25-6.
11. Agboola O. Adjuvant treatment in gastric cancer. Cancer Treat Rev 1994, 20:217-240. 10.1016/0305-7372(94)90001-9, 8020004.
12. Bonenkamp JJ, Hermans J, Sasako M, Van de Velde CJ, Welvaart K, Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H. Dutch Gastric Cancer Group: Extended lymph-node dissection for gastric cancer. N Engl J Med 1999, 340:908-914. 10.1056/NEJM199903253401202, 10089184.
13. World Cancer Research Fund and American Institute for Cancer Research. Food nutrition and the prevention of cancer: a global perspective. 1997, Washington(DC): World Cancer Research Fund.
14. Koizumi Y, Tsubono Y, Nakaya N, Kuriyama S, Shibuya D, Matsuoka H, Tsuji I. Cigarette smoking and the risk of gastric cancer: a pooled analysis of two prospective studies in Japan. Int J Cancer 2004, 112:1049-1055. 10.1002/ijc.20518, 15386347.
15. Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO, Kim WS, Jung CW, Park YS, Im YH, Sohn TS, Noh JH, Heo JS, Kim YI, Park CK, Park K. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005, 63:1279-1285. 10.1016/j.ijrobp.2005.05.005, 16099596.
16. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Banget Y. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)- positive advanced gastric cancer (GC). J Clin Oncol 2009, 27:18s. (suppl; abstr LBA4509).